



Financial Tear Sheet

Corporate Profile

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

Primary IR Contact

Justin Renz
Chief Financial Officer &
Treasurer
Zalicus Inc.
Phone: 617-301-7575

Stock Performance

ZLCS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$8.48
Change (%)	▲ 0.38 (4.69%)
Volume	15,816
52 Week Low	\$7.65
Market Cap	\$0
Rolling EPS	-1.20
PE Ratio	N/A

Shares Outstanding 0

Data as of 08/15/14 4:00 p.m. ET

Chart is not available for this symbol

Recent Headlines & Events

06/25/14 - 8:30 a.m.

[Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger](#)

06/18/14 - 8:30 a.m.

[Zalicus Licenses Sodium Channel Pain Modulation Program](#)

06/02/14 - 9:33 a.m.

[Zalicus Announces Closing of cHTS Service Business Sale to Horizon Discovery Group](#)

There are currently no events scheduled.

Board of Directors

[Mark H.N. Corrigan, M.D.](#)

[Sally W. Crawford](#)

[Frank Haydu \(Chairman\)](#)

[Bill Hunter, M.D.](#)

[Michael G. Kauffman, M.D.](#)

[W. James O'Shea](#)

Executive Management

[Mark H. N. Corrigan, M.D.](#) President and Chief Executive Officer

[Justin Renz](#) Executive Vice President and Chief Financial Officer

SEC Filings

Filing Date	Form
02/14/17	SC 13G/A
09/26/16	25-NSE
08/01/16	8-K
07/25/16	8-K

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed